Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey, it cupped, but it did not handle.
Damn, what the hell did you do to us? I thought we had it all figured out.
No more Derf sightings!
my goodness.
Looks like this is one for me to jump back into
Gap fill incoming 45 to 60
45 to 60 gap...
High probability it fills...
There’s already 6-9 months of supply in the US already and the Supply chain has not yet been impacted. Biggest impact will be the launch in Europe.
And the European launch has probably stalled
Whose filling the bottles? Working at the plants? Shipping the products? Serving the customers?
Not exactly.
I'm having trouble understanding the logic behind the sharp drop in GW. It doesn't seem that corporate revenue would be impacted that much by the corona virus. People would still suffer from epilepsy and need medication. This doesn't make sense.
You called $85!! spot on
Here’s the Real Reason Why the U.S. Federal Government Hasn’t Legalized Cannabis
click here to read
Thinking about jumping back in here. I was one of the early investors that saw the share price go from the teens to $175+ where I sold. However, the company is doing great things and the price looks compelling in the low 90’s.
Alright, I bought a small amount at $101.45.
How's this for a helpful prediction.....
This is either the absolute right time to add back some GWPH....or it isn't.
No thanks, at least not yet. Maybe at $2. I’m not catching a falling knife right now.
ZYNE no debt trading at cash only 23 million shares a wide array of results coming in the weeks ahead trading at 52 week low market cat at $90 million looks for a massive bounce last company ceo sold for a billion dollars
http://ir.zynerba.com/static-files/37d6ae9e-ea32-4cb2-8def-38ae71f266fa
Maybe, for a change, I will call this one correctly. Depending on which side you're on, this stock can make you a bundle or lose you one. I guess I've done both here.
Right now, I want no part in owning this....but maybe sooner than I thought it might be time to get back in.
They already announced these results in Jan, did you think they would change?
you are right, dropped to $109 afterhours
Charts rarely lie
It could climb if they deliver a beat
So it didn't break through resistance and now looks to be headed down again. Can't say for sure, but might be worth considering around $100. If not there, maybe $85? I think it's best for me to sit on the sidelines for a while.
Great, but GWPH isn’t a marijuana stock. Maybe post on this on Aurora, Tilray etc message boards?
$GWPH Buyer Beware: Investing In Marijuana Stocks
https://www.benzinga.com/markets/cannabis/18/09/12410236/buyer-beware-investing-in-marijuana-stocks
Cannabis is set to be legally prescribed in Scotland at the country’s first private clinic for the drug. The unit, which aims to provide medicinal cannabis for “all conditions acknowledged to benefit from it”, is scheduled to open in Aberdeen.
Medical cannabis was legalised across the UK in 2018 but its availability is strictly limited, making products difficult to access on the NHS. The Sapphire Medical Clinic will offer cannabis flowers, oil and gel to patients who are referred by GPs.
Mikael Sodergren, Sapphire’s managing director, said: “We have already seen first-hand how medical cannabis is transforming lives. That’s why we are delighted to be opening our doors to patients in Aberdeen.”
Michael Platt, a clinician specialising in pain, added: “It is estimated that over 1.4 million people across the UK take cannabis to help alleviate the symptoms of a medical condition. The overwhelming majority of these people will have felt they have had no option other than to resort to the black market, and many of them will be deeply troubled by having to do so.
“By opening the clinic in Aberdeen we will be giving patients a legal, safe and medically sound route to access what they need. The cost in some cases might be slightly higher but the patient will have the benefit of peace of mind.”
https://www.thetimes.co.uk/edition/scotland/marijuana-to-be-legally-prescribed-at-private-clinic-in-aberdeen-st6kcb75d
Top 10 Marijuana Industry News Stories of the Week
Here is your Top 10
I didn't bring it up, you did.
I don't short or assume that every stock is under a short attack either. Not sure why you brought it up. In my post I simply said the shorts could get squeezed with a 10% jump after hours.
I just looked at a chart going back to their beginning, and the claim they run every year at this time is very wrong. They did in 2019, but didn't in almost every other year.
I don't short stocks so couldn't say what a short was thinking. However, if I did, I'd be noticing the stock is bumping a double resistance level and would only be worried if it broke through there.
At least that's the reason I sold my shares.
I certainly don't assume that every stock everywhere is under a short attack. That's the cry of the penny stockholder.
This is why GWPH jumped last week. Their competitor had good results but not as good as the company expected. Also investors are starting to feel the paranoia of prescribing fen fen to kids. FEN FEN remember that stuff. This is great news for GWPH
Zogenix down 33% after hours on disappointing Fintepla data
Feb. 6, 2020 4:41 PMZogenix, Inc. (ZGNX)GWPHBy: Douglas W. House, SA News Editor
Zogenix (NASDAQ:ZGNX) slumps 33% after hours in reaction to its announcement of results from a Phase 3 clinical trial evaluating two doses of Fintepla (fenfluramine oral solution) (ZX008) in patients with a severe form of childhood-onset epilepsy called Lennox-Gastaut syndrome.
The company says the higher dose met the primary endpoint of the change from baseline in seizure frequency compared to placebo. Specifically, patients receiving 0.7 mg/kg/day experienced a median reduction of 26.5% in monthly drop seizure frequency versus 7.8% for control (p=0.0012). The proportion of patients with at least a 50% reduction in monthly drop seizures, a secondary endpoint, was 25.3% compared to 10.3% for placebo (p=0.0165).
The results for the lower dose (0.2 mg/kg/day) were not statistically significant.
Phase 2 data published in September 2018 showed a 53% median reduction in seizure frequency with 62% of treated patients experiencing at least a 50% drop (median dose of 0.4 mg/kg/day).
By comparison, 20 mg/kg/day of GW Pharmaceuticals' (GWPH +7.1%) Epidiolex (cannabidiol) resulted in a 44% median reduction drop seizure frequency (vs. 22% for placebo) (package insert data).
GW Pharmaceuticals (NASDAQ:GWPH), whose Epidiolex (cannabidiol) was approved for Lennox-Gastaut in June 2018, is up 9% after hours.
I think the run is just getting started. It seems to run about this time every year. The revenues are going to increase. The plus side is they already have an FDA approved drug. And it is only a matter of time till the same drug is approved for another medical condition IMO
I could be wrong. But taking profit is always good.
I’m not sure. But if you had short position here and seen a 10% jump after hours wouldn’t you start to worry?
Why does everyone on IHUB assume there are "shorties" behind every bush?
Hitting major resistances around $130 and $133. Half tempted to take my profit and watch.
edit: Just got out at $128. Happy with that, although it may go a bit higher still.
If it breaks above $134 it could run for a bit.
Huge after hours movement. We could see much higher tomorrow, the shorts are going to be squeezed.
Hmmmm, are we forming a cup and handle, or heading to $85? Man this stock confounds me like no other.
I'd be sick if I was trying to trade this thing. How are you feeling? You need some CBD?
I figured we'd still be hanging around 150.
Everyone cashed out on the secondary offerings and it pissed the chart off.
It's probably priced in just right by now. I knew it was going to cost a ton but the best thing GW did was to go their own way and take it all in house. No more handouts from Otsuka and the public determines the share price.
It really does come down to nuts and bolts....
If I have a child that suffers multiple seizures every day and I could give them something to make it go away, I would.
Especially if the drug doesn't have a side effect like the powerful sedatives that they still prescribe.
Even though my interests have changed over the years, I still think this company is only getting started.
I'm more passive nowadays but I'm positive that history will show that this little plant, not unlike any other, will find its place in pharmaceutical books right next to cocoa and coffee.
I'd sight the rubber tree, but I think DuPont had them all killed to make this fuggin paper.
go long and you won't go wrong.
we've been here since the IPO so
I know that you know.
from 12 to 200 and many cheese fries in between.
There ya go! You were able to include reasons why you believe it. Was that so hard?
Problem is, there's double resistance around $131 first.
I cannot predict anything, which is why there was IMO at the end of it. But a fact is I do own shares of GWPH. Also revenues are beyond what they were when this was trading higher. Epidiolex is expanding in market share. With this alone why would it not return to those prices?
Cannabis compound could be weapon in fight against superbugs
Mice cured of MRSA, raising hopes of treating antibiotic-resistant bacteria
A compound made by cannabis plants has been found to wipe out drug-resistant bacteria, raising hopes of a new weapon in the fight against superbugs.
Scientists screened five cannabis compounds for their antibiotic properties and found that one, cannabigerol (CBG), was particularly potent at killing methicillin-resistant Staphylococcus aureus (MRSA), one of the most common hospital superbugs.
Tests in the lab showed that CBG, which is not psychoactive, killed common MRSA microbes and “persister” cells that are especially resistant to antibiotics and that often drive repeat infections. The compound also cleared up hard-to-shift “biofilms” of MRSA that can form on the skin and on medical implants.
https://www.theguardian.com/society/2020/jan/19/cannabis-compound-could-be-weapon-in-fight-against-superbugs
If you can predict this, why didn't you tell us it was going down $5 today?
50% Gain within a year if you buy now. IMO
Go GWPH!!
Inverse Head and Shoulders Pattern: 2 Cannabis Stocks With Big Breakouts and Trend Reversals Today
Click here to read article
Followers
|
256
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5918
|
Created
|
04/18/13
|
Type
|
Free
|
Moderators |
GWPH Analyst Stock Ratings:
Citigroup - Target Cut from $97 to $86 - 6/30/14
Morgan Stanley - Overweight - $103 - 5/19/14 (Restated) 4/22/14 (Initiated)
Bank of America - Buy - $110 - 3/11/14
Piper Jaffray - Overweight - $147 - 6/30/14
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |